E.g., 02/21/2019
E.g., 02/21/2019

bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing

07 February, 2019

bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc.

Holiday Shipping Schedule

17 January, 2019

Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 21, 2019 in observance of Martin Luther King Jr. Day. 

BACT/ALERT® BPA and BPN have received 510(k) clearance from the FDA for quality control testing of LRAP units with BACT/ALERT® VIRTUO®

20 December, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units with the BACT/ALERT® VIRTUO® fully automated blood culture system.

Holiday Shipping Schedule

05 December, 2018

Please be advised that all bioMérieux Inc. sites will be closed on December 24 - 25, 2018 and January 1, 2019 in observance of the upcoming holidays. We encourage you to place your orders with these dates in mind to ensure you receive products as needed.

Thanksgiving Shipping Schedule

13 November, 2018

Please be advised that bioMérieux Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Thursday, November 22 and Friday, November 23.

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY® Pneumonia Panel plus. The BIOFIRE® FILMARRAY® Pneumonia Panels aid in the diagnosis of lower respiratory tract infections.

Business review for the nine months ended September 30, 2018

18 October, 2018

Marcy l'Étoile, October 18, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2018.

Media Statement: bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance

25 September, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for Disease Control and Prevention (CDC) initiative to bring government, healthcare and industry leaders together in a year-long concentrated effort to accelerate the fight against the public health threat of antimicrobial resistance (AMR).

ALERT: Hurricane Florence - Shipping & Order Update

12 September, 2018

Due to the impact of Hurricane Florence on the east coast, delivery services by national carriers have been interrupted.

bioMérieux – First-Half 2018 Results

06 September, 2018

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2018. The statements had been reviewed by the Statutory Auditors.

Pioneering Diagnostics